Literature DB >> 30377713

[Speak up for people with rare diseases: ACHSE : ACHSE, Rare Diseases Germany, and its network].

C Mundlos1.   

Abstract

Approximately 4 million children and adults in Germany suffer from a chronic rare disease. In Europe a disease is considered "rare" when it afflicts no more than 5 from 10,000 inhabitants. In some rare diseases only a handful of people are affected in Germany but in others there are thousands. Rare diseases are mostly severe, chronic and progressive diseases, affecting one or more organs and many of them are lethal. ACHSE, Rare Diseases Germany, is the alliance of and for people living with rare diseases. Since 2004 more than 120 patient organizations representing one or more rare diseases have joined under the umbrella of ACHSE. ACHSE counsels those affected and their families as well as physicians and therapists seeking advice. ACHSE is a network and addresses and represents the interests and needs of people living with rare diseases in Germany in politics and society, in medicine, research and science. Together with the Federal Ministry for Education and Research and the ACHSE, the Federal Ministry for Health founded the National Coalition for People with Rare Diseases (NAMSE) in 2010 in order to work out the first national action plan for people with rare diseases. All stakeholders of the German healthcare system took part in this national coalition. The action plan encompasses 52 suggestions for concrete actions to tackle the most urgent problems of the patients and their families. It was completed in 2013 and approved by the German Government. Since then the ACHSE has been and still is the driving force to ensure that the implementation of all measures is being done successfully.

Entities:  

Keywords:  Chronic disease; National actionplan; Patient care; Patient organisations; Research

Mesh:

Year:  2018        PMID: 30377713     DOI: 10.1007/s00108-018-0517-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  4 in total

1.  [Development, situation and perspective of self-help support in Germany].

Authors:  R Geene; E Huber; J Hundertmark-Mayser; B Möller-Bock; W Thiel
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2009-01       Impact factor: 1.513

Review 2.  [Rare diseases. Funding programs in Germany and Europe].

Authors:  Birgit Wetterauer; R Schuster
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-05       Impact factor: 1.513

3.  [Words of greeting for the new category rare diseases].

Authors:  Eva Luise Köhler
Journal:  Internist (Berl)       Date:  2018-04       Impact factor: 0.743

4.  European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects.

Authors:  M P T de Wit; S E Berlo; G J Aanerud; D Aletaha; J W Bijlsma; L Croucher; J A P Da Silva; B Glüsing; L Gossec; S Hewlett; M Jongkees; D Magnusson; M Scholte-Voshaar; P Richards; C Ziegler; T A Abma
Journal:  Ann Rheum Dis       Date:  2011-01-20       Impact factor: 19.103

  4 in total
  3 in total

1.  Study to Investigate the Knowledge of Rare Diseases among Dentists, Orthodontists, Periodontists, Oral Surgeons and Craniomaxillofacial Surgeons.

Authors:  Annemarie Kühne; Johannes Kleinheinz; Jochen Jackowski; Jeanette Köppe; Marcel Hanisch
Journal:  Int J Environ Res Public Health       Date:  2020-12-28       Impact factor: 3.390

2.  Awareness and Knowledge of Rare Diseases in German Dentists, Dental Specialists and Oral and Maxillofacial Surgeons: A Country-Wide Survey.

Authors:  Korbinian Benz; Ronny Trapp; Maximilian Voss; Marcel Hanisch; Urban Geisthoff; Jochen Jackowski
Journal:  Medicina (Kaunas)       Date:  2022-08-17       Impact factor: 2.948

Review 3.  [se-atlas.de-Medical care atlas for people with rare diseases].

Authors:  Michaela Neff; Jannik Schaaf; Niels Tegtbauer; Johanna Schäfer; Manuela Till; Thomas O F Wagner; Holm Graeßner; Christine Mundlos; Holger Storf
Journal:  Internist (Berl)       Date:  2021-07-20       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.